Vitamin B12

Methylcobalamin is a biologically active coenzyme form used directly by methionine synthase; cyanocobalamin is a stable synthetic form that must be intracellularly converted (releasing about 20 mcg of cyanide per 1000 mcg dose, which is far below any toxic threshold in normal users). For most healthy people taking oral maintenance doses, the practical difference is minimal — both correct deficiency, both normalize MMA and homocysteine, and serum B12 response is comparable (PMID 23356638). The strong marketing preference for methylcobalamin is not supported by head-to-head pharmacokinetic data in healthy users. Methylcobalamin is genuinely preferred in specific populations: Leber''s hereditary optic neuropathy, tobacco amblyopia, and users with documented conversion defects. Hydroxocobalamin is actually the best parenteral form globally (longer half-life, cyanide-binding properties), and is preferred for injections. If you feel subjectively better on methylcobalamin or have one of the specific clinical indications, use it. If cost matters and you''re otherwise healthy, cyanocobalamin is entirely adequate.

Yes, probably. The Diabetes Prevention Program Outcomes Study (PMID 26764326) demonstrated that long-term metformin (≥4 years) approximately doubles the rate of biochemical B12 deficiency (4.3% vs 2.3% on placebo), and smaller studies show metformin reduces B12 absorption by 20-30% through interference with calcium-dependent intrinsic-factor-mediated uptake in the terminal ileum. Multiple consensus guidelines now recommend periodic B12 screening in patients on chronic metformin. The practical recommendation is straightforward: if you''ve been on metformin for more than 2-4 years, take 500-1000 mcg oral B12 daily (any form is adequate), and check serum B12 plus MMA every 1-2 years. You don''t need to stop metformin — high-dose oral supplementation overcomes the absorption interference. Calcium 500-1200 mg/day has been shown to partially reverse metformin''s B12 effect (PMID 16567804), but most users don''t need specific calcium supplementation for this reason.

Vegans are functionally guaranteed to develop B12 deficiency without supplementation — Pawlak''s meta-analysis (PMID 23356638) found 52% of vegans are deficient vs <3% of omnivores. The minimum effective supplemental dose for vegans is 500-1000 mcg oral B12 daily (any form). Long-term vegans who have been supplementing adequately and have documented normal B12, MMA, and homocysteine can step down to 1000 mcg twice weekly or 2000 mcg weekly (higher dose less frequently exploits the passive-diffusion mechanism and is adequate for maintenance). Lacto-ovo-vegetarians can often maintain with 100-500 mcg daily plus dairy and egg intake, though supplementation is still recommended for insurance. Spirulina, nori, tempeh, and fermented foods contain B12 analogs that are NOT reliably bioactive in humans — do not depend on these as your B12 source. Fortified plant milks and nutritional yeast (if fortified) can provide some B12 but are not reliable substitutes for supplementation. Pregnant vegans absolutely must supplement 500-1000 mcg daily; infants of unsupplemented vegan mothers develop severe neurological damage that may be irreversible.

Serum B12 is an insensitive marker that misses a substantial fraction of functional deficiency. The more sensitive tests are methylmalonic acid (MMA) and total homocysteine — MMA above 270-400 nmol/L or homocysteine above 10-12 μmol/L suggests B12 insufficiency even with normal serum B12. Holotranscobalamin (the active B12 fraction) is the most sensitive marker where available (PMID 20978274). If you have symptoms consistent with B12 deficiency (fatigue, cognitive fog, paresthesias, mood changes, glossitis) and normal serum B12, ask for MMA and homocysteine testing. A therapeutic trial is also reasonable: take 1000 mcg methylcobalamin daily for 6-8 weeks and track symptoms. Most deficient users notice improvement within 2-4 weeks. Be aware that folic acid supplementation (from fortified foods or prenatal vitamins) can correct the macrocytic anemia of B12 deficiency while masking it, which is why testing MMA and homocysteine is important rather than relying on complete blood count alone.

Oral B12 at adequate doses (1000-2000 mcg/day) is equivalent to intramuscular injections for most patients, including those with pernicious anemia (PMID 9694707). This is because passive diffusion across the intestinal mucosa absorbs approximately 1-2% of any oral dose regardless of intrinsic factor status, so a 2000 mcg oral dose delivers 20-40 mcg systemically — well above daily requirements. Injections are genuinely preferred in a few scenarios: severe acute neurological symptoms where rapid tissue repletion matters; patients with very severe malabsorption from extensive ileal resection or radiation enteritis; patients with poor medication adherence; and situations where insurance/access makes monthly IM more convenient than daily oral. Many patients with pernicious anemia do well on either approach and can switch based on preference, provided they verify continued normal MMA and homocysteine on whatever regimen they choose. The bias toward injections for pernicious anemia is partially historical — B12 pills weren''t available at adequate doses when pernicious anemia treatment protocols were established.

Yes — B12, folate, and B6 reliably lower homocysteine by 25-30%, with B12 typically the dominant contributor in deficient older adults. However, the clinical significance depends on what you''re trying to achieve. For preventing cardiovascular events, the large homocysteine-lowering trials (HOPE-2, VISP, VITATOPS) have largely failed to show benefit in folate-replete populations — lowering homocysteine does not, on current evidence, reduce heart attack or cardiovascular death (PMID 28816361). For cognitive benefit, the VITACOG trial (PMID 20838622) showed a 30% reduction in brain atrophy and improved cognitive function in elderly patients with mild cognitive impairment and elevated homocysteine treated with high-dose B12/folate/B6 for two years. The practical synthesis: if your homocysteine is elevated, identify and correct the underlying B-vitamin deficiency (usually B12 or folate); the biochemical improvement is almost universal; the clinical benefit is strongest for early cognitive decline in deficient elderly, modest for stroke prevention, and essentially absent for heart attack prevention in already folate-replete populations. Standard dosing is B12 500-1000 mcg + folate 400-800 mcg + B6 10-25 mg daily.

Practically, no. The Institute of Medicine has not established an upper limit because no meaningful toxicity has been observed even at very high intakes. Doses of 10,000 mcg daily (50x the RDA) have been used in trials without adverse events. Excess B12 is cleared in urine and does not accumulate to dangerous levels. There are a few caveats: high-dose B12 (particularly injections) can precipitate or worsen acne in some users (PMID 25720358); very high doses can mask folate deficiency diagnostically if folate is also inadequate; and observational data have raised weak, inconsistent signals about potential cancer associations at extreme doses, which are not established as causal. For healthy users, doses above 2000 mcg/day offer no additional benefit over 1000-2000 mcg and are mostly a waste of money. Staying in the 500-2000 mcg daily range is safe, effective, and economical for nearly all purposes.

Probably not in any meaningful way. The common belief that B12 is an ''energy vitamin'' and B12 injections boost stamina in non-deficient users is largely a placebo effect. Controlled trials of B12 in non-deficient subjects consistently show no benefit on fatigue, exercise performance, or subjective energy. The apparent energy boost from B12 injections reported by some users likely reflects a combination of placebo, demand characteristics, and perhaps vitamin-injection ritual effects, rather than any physiological improvement. The scenario where B12 dramatically improves energy is correction of actual deficiency — users with low MMA/homocysteine/holotranscobalamin or symptomatic deficiency commonly describe major fatigue and cognitive improvement within 2-6 weeks of starting therapy. If you''re a healthy, well-nourished person with normal B12 status and you''re tired, B12 injections are not the answer; investigate sleep, exercise, thyroid, iron, depression, and other common causes of fatigue before concluding that B12 will help.

Almost certainly not, despite extensive marketing to this effect. MTHFR polymorphisms (particularly C677T and A1298C) affect the folate cycle by reducing methylenetetrahydrofolate reductase activity, which produces modest accumulation of homocysteine and modest reduction of 5-methyltetrahydrofolate. These polymorphisms do not directly affect B12 metabolism, and there is no compelling evidence that people with MTHFR variants require methylcobalamin specifically rather than cyanocobalamin or hydroxocobalamin. MTHFR variants may modestly favor methylfolate (L-5-MTHF) over folic acid supplementation for folate repletion, but the B12 form choice is largely independent. The ''methyl-B12 for MTHFR'' recommendation is a marketing-driven pseudo-medicalization of a very common polymorphism (the heterozygous C677T occurs in 30-40% of the population) that has modest, inconsistent clinical significance. If you have MTHFR and elevated homocysteine, 500-1000 mcg of any form of B12 plus 400-800 mcg methylfolate or folic acid daily is appropriate and well-supported. If you subjectively prefer methyl-B12, there''s no harm in using it, but don''t pay a large premium for it based on MTHFR testing alone.

Yes, for the overwhelming majority of users. B12 has been used as daily maintenance supplementation in pernicious anemia patients for more than 70 years, and long-term daily high-dose therapy (500-2000 mcg/day) has one of the best safety records of any supplement in clinical use. No tolerance develops, no accumulation toxicity occurs, and stopping therapy after long-term use produces no rebound phenomena. The rare issues to monitor are: acneiform skin reactions (reduce dose or switch form if they appear); allergic reactions (rare but require form changes or discontinuation); and the ongoing background concern about very-high-dose B-vitamin supplementation and cancer in specific populations (weakly supported, not a reason to avoid normal dosing). The adult over 50 population has the strongest indication for indefinite B12 supplementation given the progressive decline in food-bound B12 absorption with aging atrophic gastritis; starting 500-1000 mcg daily in your 50s and continuing indefinitely is a reasonable default. Periodic MMA and homocysteine checks every 2-5 years confirm continued adequacy; serum B12 will be elevated on supplementation and is not a useful tracking marker.